SREBF1 and cancer: This compound is an example of a potent small molecule that is unlikely to be repurposed for SREBP1-based cancer prevention, due to its toxicity; however, it is a proof of concept that lowering neddylation of SREBP1 can be a druggable target with potential cancer-preventive effects.